Drug Profile
PT 5
Latest Information Update: 22 Mar 2007
Price :
$50
*
At a glance
- Originator Palatin Technologies
- Class Radiopharmaceuticals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Lung cancer
Most Recent Events
- 10 Apr 2000 Palatin Technologies has received the US patent covering MIDAS technology
- 01 Dec 1998 Phase-I clinical trials for Lung cancer in Germany (Unknown route)